35 assets in Malignant Pleural Mesothelioma

Therapeutic assets addressing Malignant Pleural Mesothelioma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii Malignant Pleural Mesothelioma	AstraZeneca	P2	BB (71)
Carboplatin Malignant Pleural Mesothelioma	AstraZeneca	P2	BB (67)
Fluorouracilum Malignant Pleural Mesothelioma	Memorial Sloan Kettering Cancer Center	P2	B (60)
Pembrolizumab Malignant Pleural Mesothelioma	NuCana plc	P2	B (60)
Atezolizumab Malignant Pleural Mesothelioma	Swiss Cancer Institute	P2	B (57)
Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific Malignant Pleural Mesothelioma	M.D. Anderson Cancer Center	P2	CCC (53)
Regorafenib Malignant Pleural Mesothelioma	Translational Research in Oncology	P2	CCC (53)
Tislelizumab Malignant Pleural Mesothelioma	Translational Research in Oncology	P2	CCC (53)
ctx131 Malignant Pleural Mesothelioma	CRISPR Therapeutics AG	P1/2	CCC (52)
Ipilimumab Malignant Pleural Mesothelioma	Memorial Sloan Kettering Cancer Center	P1/2	CCC (52)
Nivolumab Malignant Pleural Mesothelioma	Memorial Sloan Kettering Cancer Center	P1/2	CCC (52)
Cyclophosphamide Malignant Pleural Mesothelioma	Beijing Biotech	P1/2	CCC (48)
Eb-Mf-Car-Nk-01 Malignant Pleural Mesothelioma	Beijing Biotech	P1/2	CCC (48)
Fludarabine Malignant Pleural Mesothelioma	Beijing Biotech	P1/2	CCC (48)
Methoxyamine Malignant Pleural Mesothelioma	National Cancer Institute (NCI)	P1/2	CCC (48)
Rso-021 Malignant Pleural Mesothelioma	RS Oncology LLC	P1/2	CCC (48)
Alintegimod Malignant Pleural Mesothelioma	7 Hills Pharma, LLC	P1/2	CC (47)
Docetaxel Malignant Pleural Mesothelioma	NuCana plc	P1/2	CC (47)
Mdna11 Malignant Pleural Mesothelioma	Medicenna Therapeutics, Inc.	P1/2	CC (47)
1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)- Malignant Pleural Mesothelioma	Nurix Therapeutics, Inc.	P1	CC (43)
Amt-151 Malignant Pleural Mesothelioma	Multitude Therapeutics Inc.	P1	CC (43)
Apg 2449 Malignant Pleural Mesothelioma	Ascentage Pharma Group Inc.	P1	CC (43)
Benzenesulfonamide, N-Methyl-3-(1-Methyl-1H-Imidazol-4-Yl)-4-[[[4-(Trifluoromethyl)Phenyl]Methyl]Amino]- Malignant Pleural Mesothelioma	Ikena Oncology	P1	CC (43)
Bms-986504 Malignant Pleural Mesothelioma	Memorial Sloan Kettering Cancer Center	P1	CC (43)
ct-95 Malignant Pleural Mesothelioma	Context Therapeutics Inc.	P1	CC (43)
Elimusertib Malignant Pleural Mesothelioma	National Cancer Institute (NCI)	P1	CC (43)
ide892 Malignant Pleural Mesothelioma	IDEAYA Biosciences	P1	CC (43)
MAT2A-IN-9 Malignant Pleural Mesothelioma	IDEAYA Biosciences	P1	CC (43)
mt027 Malignant Pleural Mesothelioma	Suzhou Maximum Bio-tech Co., Ltd.	P1	CC (43)
Osimertinib Malignant Pleural Mesothelioma	Ikena Oncology	P1	CC (43)
Oxaliplatin Malignant Pleural Mesothelioma	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Fosifloxuridine Nafalbenamide Malignant Pleural Mesothelioma	NuCana plc	P1/2	CC (40)
Human Interleukin 2 (Il2, T-Cell Growth Factor, Tcgf) (2-133) Variant (A1 Deleted, Pro65>Lys, Cys125>Ser), Non-Glycosylated, Produced In Escherichia Coli, Conjugated At N6 Of K65 With A Peg Derivative (30Kda) Malignant Pleural Mesothelioma	Sanofi	P2	D (31)
Volrustomig Malignant Pleural Mesothelioma	AstraZeneca	P2	NR ()